ALK-Abelló A/S (CPH:ALK.B)

Market Cap	36.34B
Revenue (ttm)	5.71B
Net Income (ttm)	937.00M
Shares Out	221.19M
EPS (ttm)	4.18
PE Ratio	39.29
Forward PE	30.45
Dividend	n/a
Ex-Dividend Date	n/a

Volume	198,259
Average Volume	213,358
Open	162.60
Previous Close	163.90
Day's Range	159.30 - 165.00
52-Week Range	130.70 - 185.60
Beta	0.59
RSI	66.43
Earnings Date	May 6, 2025

About ALK-Abelló

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mites, grass and tree pollen, ragweed, Japanese cedar, and food. It also provides consumer healt...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1923
• Employees: 2,753
• Stock Exchange: Copenhagen Stock Exchange
• Ticker Symbol: ALK.B

Financial Performance

In 2024, ALK-Abelló's revenue was 5.54 billion, an increase of 14.78% compared to the previous year's 4.82 billion. Earnings were 815.00 million, an increase of 67.70%.